EMA Accepts Asieris' Marketing Application for Cevira in Europe
Event summary
- Asieris Pharmaceuticals' Marketing Authorization Application (MAA) for Cevira (APL-1702) accepted by the European Medicines Agency (EMA) on February 27, 2026.
- Cevira is a photodynamic drug-device combination for treating high-grade squamous intraepithelial lesions (HSIL).
- The MAA submission is supported by Phase III clinical trial results, with over 20% European patient enrollment.
- Photocure licensed Cevira to Asieris in 2019, with Asieris initiating Phase III trials in November 2020.
The big picture
The EMA's acceptance of the MAA for Cevira marks a significant milestone in the non-surgical treatment of HSIL, a condition with limited therapeutic options. This development underscores the strategic value of Photocure's licensing deal with Asieris, positioning both companies to capitalize on the growing demand for innovative solutions in women's health. The acceptance also highlights the increasing role of photodynamic therapy in precision medicine, potentially expanding treatment avenues beyond bladder cancer into other oncological and gynecological indications.
What we're watching
- Regulatory Timeline
- The pace at which the EMA completes its review and grants marketing authorization for Cevira.
- Commercialization Strategy
- How Asieris plans to launch Cevira in Europe, including pricing and market penetration tactics.
- Revenue Impact
- The potential revenue contribution of Cevira to Asieris' and Photocure's financials post-approval.
Related topics